Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT03656835

Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma

A Pilot Study of Nanochip Technology for Monitoring Treatment Response and Detection of Relapse in Patients With Diffuse Large B-Cell Lymphoma

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
73 (actual)
Sponsor
Ohio State University Comprehensive Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This trial studies how well nanochip technology (immuno-tethered lipoplex nanoparticle \[ILN\] biochip) works in monitoring treatment response and in detecting relapse in participants with diffuse large B-cell lymphoma. Finding genetic markers for diffuse large B-cell lymphoma may help identify participants with this disease and help predict the outcome of treatment. It is not yet known how well ILN biochip-based testing monitors treatment response or detects relapse in participants with diffuse large B-cell lymphoma.

Detailed description

PRIMARY OBJECTIVES: I. Determine whether ILN biochip can be used to detect molecular marker(s) to monitor treatment response in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). II. Determine whether ILN biochip can promote early detection of disease relapse in patients with DLBCL. OUTLINE: Participants' blood samples undergo ILN biochip testing at diagnosis, before and after every course of chemotherapy, every 3 months for 2 years, and at relapse.

Conditions

Interventions

TypeNameDescription
PROCEDUREMolecular NanotechnologyUndergo ILN biochip testing

Timeline

Start date
2018-09-26
Primary completion
2024-11-20
Completion
2026-07-01
First posted
2018-09-04
Last updated
2025-12-18

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03656835. Inclusion in this directory is not an endorsement.